glp 1 nejm GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Orforglipron, an Oral Small-Molecule GLP-1
Description
Although Ozempic and Wegovy both contain the active ingredient Semaglutide, they are intended for different purposes and so have different dosages to reflect this

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators

Doctor-trusted GLP-1 for Weight Loss

Does Medicare cover GLP-1 medications for weight loss

#ad Curious if your insurance covers GLP-1s
